Morgan Lewis Advises GlaxoSmithKline in Arrowhead Pharmaceuticals License Agreement

PRINCETON, November 24, 2021: Morgan Lewis is advising GlaxoSmithKline in an exclusive license agreement with Arrowhead Pharmaceuticals Inc. under which GSK will develop and commercialize ARO-HSD, Arrowhead’s investigational RNA interference (RNAi) therapeutic in a Phase 1/2 trial that is currently being developed as a treatment for patients with nonalcoholic steatohepatitis.

Morgan Lewis partner Amanda Goceljak—along with partners Jennifer Feldsher and Todd Liao, and associate Mudan He—are representing GSK.

For more, read the announcement.